Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation

• Status: Recruiting
• Trial end date: 2024-03-21
• Target enrollment: 0
• Participant gender: All

Summary

Kidney transplantation is the best available treatment option for patients with end stage renal disease. However, kidney transplantation requires life-long use of immunosuppressive medication. Because of the high cost of these medications we need to carefully evaluate the cost-effectiveness of each drug regimen, especially in low-middle income countries. The objective of this clinical trial is to compare the efficiency and cost of two immunosuppressive protocols after living donor kidney transplantation: (1) antithymocyte globulin, tacrolimus, azathioprine and prednisolone versus (2) basiliximab, tacrolimus, mycophenolate mofetil and prednisolone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Khartoum
• Collaborator: National Center for Kidney Diseases and Surgery
• Treatments: Antibodies; Antibodies, Monoclonal; Antilymphocyte Serum; Azathioprine; Basiliximab; Immunoglobulins; Immunoglobulins, Intravenous; Interleukin-2; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Mycophenolic Acid; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Tacrolimus; Thymoglobulin

Criteria

Inclusion Criteria:

• Adult end-stage renal disease patients

• First living donor kidney transplant.

• Moderate immunological risk.

Exclusion Criteria:

• Low immunological risk (HLA mismatches 000/100/010/110 with negative PRA).

• High immunological risk (child to mother or husband to wife transplant, 2 DR mismatches).

• Known hypersensitivity to any of the study medication.